A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Vitiligo (Active and Stable)

Status:
Not yet recruiting

Trial end date:
2025-06-19

Target enrollment:

Participant gender:

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Vitiligo (Active and Stable)

Phase 3

Pfizer